Asia Fresh News

Asia Fresh Stories

Archive for March 11th, 2011

Published Data from e-HEALING Registry Demonstrate Good Clinical Outcomes with Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeich’s Genous(TM) Stent

leave a comment »

12-Month Data from Worldwide Registry Published in February Issue of EuroIntervention

HONG KONG, March 11, 2011 /PRNewswire-Asia/ — OrbusNeich today announced that 12-month follow-up data from the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) registry published in the February issue of EuroIntervention demonstrated good clinical outcomes with low incidence of repeat revascularization and stent thrombosis (ST) for the company’s Genous Stent.

Target vessel failure (TVF), defined as target vessel-related cardiac death or myocardial infarction (MI) and target vessel revascularization (TVR), was 8.4 percent at 12 months. The composite of death, MI or target lesion revascularization (TLR) occurred in 7.9 percent of the patients. TLR and ST were 5.7 percent and 1.1 percent, respectively.

“The good clinical outcomes for the Genous Stent in real-world use, especially the low incidence of stent thrombosis, demonstrate that the pro-healing approach of the Genous Stent is effective for a range of challenging patient groups,” said Professor Sigmund Silber, M.D., Ph.D., of the Kardiologische Klinik Dr Muller, Munich, co-principal investigator and one of the lead authors of the publication. “As shown previously in several subset analyses of the e-HEALING registry, the Genous Stent produces exceptional outcomes in diabetic and elderly patients.”

e-HEALING, a multi-center, worldwide prospective clinical registry conducted in 31 countries outside of the United States at 144 centers, included 4,939 patients with at least one lesion suitable for non-urgent percutaneous coronary intervention (PCI) and Genous Stent implantation. The mean age of the study population was 63 years, and 79 percent of patients were male. In addition, 25 percent of patients in the study cohort had diabetes mellitus, and 37 percent had a prior MI. On average, 1.3 lesions per patient were treated – 97.7 percent were de novo lesions, and 10 percent were bifurcation lesions. For the lesions treated, 49 percent were type B2/C lesions. At the 30-day visit, 83 percent of the patients were on dual anti-platelet therapy (DAPT), 59 percent at six months and 34 percent at 12 months, respectively. The 12-month primary outcome was TVF, and secondary outcomes included composite of cardiac death, MI or TLR, and individual outcomes, including ST.

The Genous Stent is featured in two additional publications in the February issue of EuroIntervention. Scacciatella et al. reported on a single center registry with two-year outcomes in 61 patients with a high risk for restenosis who cannot receive drug-eluting stents for various reasons, including those who need surgery within two months and those with a high bleeding risk or who are allergic to aspirin. Martin-Yuste et al. presented another single center registry involving 78 patients with high comorbidities who required chronic anticoagulation due to atrial fibrillation, mechanical valve prosthesis, cardiomyopathy or prior emboli.

The Genous Stent was also featured in the editorial by Emanuele Barbato, M.D., Ph.D., and William Wijns, M.D., Ph.D., of the Cardiovascular Center, Aalst, Belgium, and in the introduction written by Patrick W. Serruys, M.D., Ph.D., of the Erasmus Medical Center, Rotterdam, the Netherlands, who is editor-in-chief of EuroIntervention.

About Genous

Genous is OrbusNeich’s patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world’s first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Blazer(TM), R stent, Scoreflex(TM), Sapphire(TM) and Sapphire NC. Development stage products include the Combo(TM) Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit


Written by asiafreshnews

March 11, 2011 at 5:42 pm

Posted in Uncategorized

Tagged with

Vinay Shenoy Appointed as Managing Director for Infineon Technologies India

leave a comment »

Vinay Shenoy Appointed as Managing Director for Infineon Technologies India
2011-03-10 11:00
BANGALORE, India, March 10, 2011 /PRNewswire-Asia/ — Infineon Technologies announced the appointment of Vinay Shenoy as the Managing Director for Infineon Technologies India effective from 1st February.

Vinay Shenoy, Managing Director of Infineon Technologies India

Vinay Shenoy assumes responsibilities for driving the growth of Infineon business in India focusing on energy efficiency, mobility and security in addition to Research & Development. “Infineon is already the global #1 in semiconductors solutions for the automotive, power & energy and chip card markets. We will leverage our global capability and enhance local reach to rapidly strengthen Infineon’s position in the India market. We will work closely with our strategic customers across energy efficiency, mobility and security sectors by expanding the scope of our offerings and thereby play a bigger role in their success,” said Vinay Shenoy.

About Vinay Shenoy

Vinay Shenoy is a graduate in electronics engineering and a post graduate in computer engineering. He has over twenty years experience in driving business growth and innovation within the semiconductors, consumer electronics and telecommunications industries. He has worked in various roles at Texas Instruments, Philips Electronics and SemIndia. He has a proven track record in establishing business & Innovation in large multinationals as well as startups with wide ranging experience in marketing & sales, product strategy & development, business development and partnerships.

About Infineon India

Infineon Technologies India Pvt. Ltd. was established in Bangalore in 1997. Today, it is a major centre within Infineon’s global R&D network. It plays a vital role in software and hardware development for global products. It also has satellite offices in Pune and New Delhi to develop and service the Indian market.

Infineon India currently employs about 250 highly qualified professionals, working in the area of leading-edge and innovative technology development for Automotive Electronics, Secured ID and Smartcards. Infineon India business team operates as the gateway into the Indian Market for Infineon Technologies, which has a significant market presence in India and is among the top 10 semiconductor players providing Marketing, Sales & Application support for a wide range of customers in the automotive, industrial, consumer electronics and smartcard industries.

About Infineon

Infineon Technologies AG, Neubiberg, Germany, offers semiconductor and system solutions addressing three central challenges to modern society: energy efficiency, mobility, and security. In the 2010 fiscal year (ending September 30), the company reported sales of Euro 3.295 billion with approximately 26,650 employees worldwide. With a global presence, Infineon operates through its subsidiaries in the U.S. from Milpitas, CA, in the Asia-Pacific region from Singapore, and in Japan from Tokyo. Infineon is listed on the Frankfurt Stock Exchange (ticker symbol: IFX) and in the USA on the over-the-counter market OTCQX International Premier (ticker symbol: IFNNY).

Further information is available at

SOURCE Infineon Technologies

Written by asiafreshnews

March 11, 2011 at 10:35 am

Posted in Uncategorized